|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastroenterologist perceptions of faecal microbiota transplantation显示文摘AIM: To explore gastroenterologist perceptions towards and experience with faecal microbiota transplantation(FMT).METHODS: A questionnaire survey consisting of 17 questions was created to assess gastroenterologists' attitude towards and experience with FMT. This was anonymously distributed in hard copy format amongst attendees at gastroenterology meetings in Australia between October 2013 and April 2014. Basic descriptive statistical analyses were performed.RESULTS: Fifty-two clinicians participated. Twenty one percent had previously referred patients for FMT,8% more than once. Ninety percent would refer patients with Clostridium difficile infection(CDI) for FMT if easily available,37% for ulcerative colitis,13% for Crohn's disease and 6% for irritable bowel syndrome. Six percent would not refer any indication,including recurrent CDI. Eighty-six percent would enroll patients in FMT clinical trials. Thirty-seven percent considered the optimal mode of FMT administration transcolonoscopic,17% nasoduodenal,13% enema and 8% oral capsule. The greatest concerns regarding FMT were: 42% lack of evidence,12% infection risk,10% non infectious adverse effects/lack of safety data,10% aesthetic,10% lack of efficacy,4% disease exacerbation,and 2% inappropriate use; 6% had no concerns. Seventy seven percent believed there is a lack of accessibility while 52% had an interest in learning how to provide FMT. Only 6% offered FMT at their institution.CONCLUSION: Despite general enthusiasm,most gastroenterologists have limited experience with,or access to,FMT. The greatest concerns were lack of supportive evidence and safety issues. However a significant proportion would refer indications other than CDI for FMT despite insufficient evidence. These data provide guidance on where education and training are required. | Sudarshan Paramsothy Alissa J Walsh Thomas Borody Douglas Samuel Johan van den Bogaerde Rupert WL Leong Susan Connor Watson Ng Hazel M Mitchell Nadeem O Kaakoush Michael A Kamm | 2015 | World Journal of Gastroenterology2015，21，38： | 5 |
| 2 | Anemia and iron deficiency in gastrointestinal and liver conditions显示文摘Iron deficiency anemia(IDA) is associated with a number of pathological gastrointestinal conditions other than inflammatory bowel disease, and also with liver disorders. Different factors such as chronic bleeding, malabsorption and inflammation may contribute to IDA. Although patients with symptoms of anemia are frequently referred to gastroenterologists, the approach to diagnosis and selection of treatment as well as follow-up measures is not standardized and suboptimal. Iron deficiency, even without anemia, can substantially impact physical and cognitive function and reduce quality of life. Therefore, regular iron status assessment and awareness of the clinical consequences of impaired iron status are critical. While the range of options for treatment of IDA is increasing due to the availability of effective and well-tolerated parenteral iron preparations, a comprehensive overview of IDA and its therapy in patients with gastrointestinal conditions is currently lacking. Furthermore, definitions and assessment of iron status lack harmonization and there is a paucity of expert guidelines on this topic. This review summarizes current thinking concerning IDA as a common co-morbidity in specific gastrointestinal and liver disorders, and thus encourages a more unified treatment approach to anemia and iron deficiency, while offering gastroenterologists guidance on treatment options for IDA in everyday clinical practice. | Jürgen Stein Susan Connor Garth Virgin David Eng Hui Ong Lisandro Pereyra | 2016 | World Journal of Gastroenterology2016，22，35： | 5 |
| 3 | Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video)显示文摘 | Anne F. Peery Toshitaka Hoppo Katherine S. Garman Evan S. Dellon Norma Daugherty Susan Bream Alejandro F. Sanz Jon Davison Melissa Spacek Diane Connors Ashley L. Faulx Amitabh Chak James D. Luketich Nicholas J. Shaheen Blair A. Jobe | 2012 | Gastrointestinal Endoscopy2012，，5： | 2 |
| 4 | Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease显示文摘BACKGROUND Tumor necrosis factor-alpha inhibitors,including infliximab and adalimumab,are effective medical treatments for perianal fistulising Crohn’s disease(CD),but not all patients achieve fistula healing.AIM To determine the correlation between perianal fistula healing and closure with infliximab and adalimumab trough levels.METHODS In this multicentre retrospective study conducted across four tertiary inflammatory bowel disease centres in Australia,we identified CD patients with perianal fistulae on maintenance infliximab or adalimumab who had a trough level within twelve weeks of clinical assessment.Data collected included demographics,serum infliximab and adalimumab trough levels(mg/L)within 12 wk before or after their most recent clinical assessment and concomitant medical or surgical therapy.The primary outcome was fistula healing,defined as cessation in fistula drainage.The secondary outcome was fistula closure,defined as healing and closure of all external fistula openings.Differences between patients who did or did not achieve fistula healing were compared using the chi-square test,t test or Mann-Whitney U test.RESULTS One hundred and fourteen patients(66 infliximab,48 adalimumab)were included.Forty-eight(72.7%)patients on maintenance infliximab achieved fistula healing and 18(27.3%)achieved fistula closure.Thirty-seven(77%)patients on maintenance adalimumab achieved fistula healing and 17(35.4%)achieved fistula closure.Patients who achieved fistula healing had significantly higher infliximab and adalimumab trough levels than patients who did not[infliximab:6.4(3.8-9.5)vs 3.0(0.3-6.2)mg/L,P=0.003;adalimumab:9.2(6.5-12.0)vs 5.4(2.5-8.3)mg/L,P=0.004].For patients on infliximab,fistula healing was associated with lower rates of detectable anti-infliximab antibodies and younger age.For patients on adalimumab,fistula healing was associated with higher rates of combination therapy with an immunomodulator.Serum trough levels for patients with and without fistula closure were not significantly different for infliximab[6.9(4.3-10.2)vs 5.5(2.5-8.3)mg/L,P=0.105]or adalimumab[10.0(6.6-12.0)vs 7.8(4.2-10.0)mg/L,P=0.083].CONCLUSION Higher maintenance infliximab and adalimumab trough levels are associated with perianal fistula healing in CD. | Bonita Gu Kavya Venkatesh Astrid-Jane Williams Watson Ng Crispin Corte Ali Gholamrezaei Simon Ghaly Wei Xuan Sudarshan Paramsothy Susan Connor | 2022 | World Journal of Gastroenterology2022，28，23： | 2 |
| 5 | Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford显示文摘BACKGROUND Vedolizumab(VDZ),a humanised monoclonal antibody that selectively inhibits alpha4-beta7 integrins is approved for use in adult moderate to severe ulcerative colitis(UC)patients.AIM To assess the efficacy and safety of VDZ in the real-world management of UC in a large multicenter cohort involving two countries and to identify predictors of achieving remission.METHODS A retrospective review of Australian and Oxford,United Kingdom data for UC patients.Clinical response at 3 mo,endoscopic remission at 6 mo and clinical remission at 3,6 and 12 mo were assessed.Cox regression models and Kaplan Meier curves were performed to assess the time to remission,time to failure and the covariates influencing them.Safety outcomes were recorded.RESULTS Three hundred and three UC patients from 14 centres in Australia and United Kingdom,[60%n=182,anti-TNF naïve]were included.The clinical response was 79%at 3 mo with more Australian patients achieving clinical response compared to Oxford(83%vs 70%P=0.01).Clinical remission for all patients was 56%,62%and 60%at 3,6 and 12 mo respectively.Anti-TNF naive patients were more likely to achieve remission than exposed patients at all the time points(3 mo 66%vs 40%P<0.001,6 mo 73%vs 46%P<0.001,12 mo 66%vs 51%P=0.03).More Australian patients achieved endoscopic remission at 6 mo compared to Oxford(69%vs 43%P=0.01).On multi-variate analysis,anti-TNF naïve patients were 1.8(95%CI:1.3-2.3)times more likely to achieve remission than anti-TNF exposed(P<0.001).32 patients(11%)had colectomy by 12 mo.CONCLUSION VDZ was safe and effective with 60%of UC patients achieving clinical remission at 12 mo and prior anti-TNF exposure influenced this outcome. | Samba Siva Reddy Pulusu Ashish Srinivasan Krupa Krishnaprasad Daniel Cheng Jakob Begun CharlotteKeung Daniel Van Langenberg Lena Thin Tamara Mogilevski Peter De Cruz Graham Radford-Smith Emma Flanagan Sally Bell Soleiman Kashkooli Miles Sparrow Simon Ghaly Peter Bampton Elise Sawyer Susan Connor Quart-ul-ain Rizvi Jane M Andrews Gillian Mahy Paola Chivers Simon Travis Ian Craig Lawrance | 2020 | World Journal of Gastroenterology2020，26，30： | 2 |
| 6 | The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5)显示文摘 | Kathy A. Hodgkinson Patrick S. Parfrey Anne S. Bassett Christine Kupprion J?rg Drenckhahn Mark W. Norman Ludwig Thierfelder Susan N. Stuckless Elizabeth L. Dicks William J. McKenna Sean P. Connors | 2005 | Journal of the American College of Cardiology2005，，3： | 1 |
| 7 | Evaluation of four methods of warming intravenous fluids显示文摘 | Lisa Marie Bernardo Kathleen o'connor Susan Serelka | 1995 | Emergency nerses association1995，21，： | 1 |
| 8 | Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep:Does underlying inflammatory bowel disease impact tolerability and efficacy?显示文摘BACKGROUND Colonoscopy remains the gold standard for detection of colonic disease.An optimal evaluation depends on adequate bowel cleansing.Patients with inflammatory bowel disease(IBD),require frequent endoscopic assessment for both activity and dysplasia assessment.Two commonly used bowel preparations in Australia are Prep Kit-C(Pc)and Moviprep(Mp).Little is known about tolerability,efficacy and safety of split protocols of Mp and Pc in both IBD and non-IBD patients.AIM To primary aim was to compare the tolerability,efficacy and safety of split protocols of Mp and Pc in patients having a colonoscopy.The secondary aim was to compare the efficacy,tolerability and safety of either preparation in patients with or without IBD.METHODS Patients were randomized to Pc or Mp bowel preparation.Patients completed a questionnaire to assess tolerability.Efficacy was assessed using the Ottawa Bowel Preparation Score.Serum electrolytes and renal function were collected one week prior to colonoscopy and on the day of colonoscopy.RESULTS Of 338 patients met the inclusion criteria.Of 168 patients randomized to Mp and 170 to Pc.The efficacy of bowel preparation(mean Ottawa Bowel Preparation Score)was similar between Mp(5.4±2.4)and Pc(5.1±2.1)(P=0.3).Mean tolerability scores were similar in Mp(11.84±5.4)and Pc(10.99±5.2;P=0.17).125 patients had IBD(73 had Crohn’s Disease and 52 had Ulcerative colitis).Sixtyfour IBD patients were allocated to Mp and 61 to Pc.In non-IBD patients,104 were allocated to Mp and 109 to Pc.The mean tolerability score in the IBD group was lower than the non-IBD group(mean tolerability scores:IBD:10.3±5.1 and non-IBD:12.0±5.3;P=0.01).IBD patients described more abdominal pain with Mp when compared with Pc;(Mp:5.7±4.4 vs Pc:3.6±2.6,P=0.046).Serum magnesium level increased with Pc compared with Mp in all patients(mean increase in mmol/L:Mp:0.03±0.117 and Pc:0.11±0.106;P<0.0001).CONCLUSION In this study,the efficacy,tolerability and safety of Mp and Pc were similar in all patients.However,patients with IBD reported lower tolerability with both preparations.Specifically,IBD patients had more abdominal pain with Mp.These results should be considered when recommending bowel preparation especially to IBD patients. | Waled Mohsen Astrid-Jane Williams Gabrielle Wark Alexandra Sechi Jenn-Hian Koo Wei Xuan Milan Bassan Watson Ng Susan Connor | 2021 | World Journal of Gastroenterology2021，27，11： | 1 |
| 9 | Electrocantery as a factor in seroma formation following mastectomy 显示文摘 | Kathaleen AP Susan O connor | 1998 | Am J Surg1998，176，1： | 1 |
| 10 | Bowel care practices in chronic spinal cord injury patients显示文摘 | Steven C. Kirshblum Mohan Gulati Kevin C. O’Connor Susan J. Voorman | 1998 | Archives of Physical Medicine and Rehabilitation1998，，1： | 1 |
| 11 | Collegiality,Collaboration and Kuleana:Complexity in a Professional Development School显示文摘 | Connors Susan Stanley Kyed Michael P.Marlow | | 0，，04： | 1 |
| 12 | Current State of Knowledge: Language and Literacy of Children with Hearing Impairment显示文摘 | Mary Pat Moeller J Bruce Tomblin Christine Yoshinaga-Itano Carol McDonald Connor Susan Jerger | 2007 | Ear and Hearing2007，，6： | 1 |
| 13 | Clinical and Pathologic Outcomes of Colorectal Cancer in a Multi-Ethnic Population显示文摘 | Jenn Hian Koo Siu Kin Cyril Wong Bin Jalaludin Andrew Kneebone Susan J. Connor Rupert W.L. Leong | 2008 | Clinical Gastroenterology and Hepatology2008，，9： | 1 |
| 14 | Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF)显示文摘 | Carpenter Brittany L. Chen Min Knifley Teresa Davis Kelley A. Harrison Susan M. W. Stewart Rachel L. O’Connor Kathleen L | 2015 | Journal of Biological Chemistry2015，，45： | 1 |
| 15 | Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart Failure: The Sleep Heart Health Study显示文摘 | Daniel J. Gottlieb Gayane Yenokyan Anne B. Newman George T. O?Connor Naresh M. Punjabi Stuart F. Quan Susan Redline Helaine E. Resnick Elisa K. Tong Marie Diener-West Eyal Shahar | 2010 | Circulation2010，，4： | 1 |
| 16 | The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5)显示文摘 | Kathy A. Hodgkinson Patrick S. Parfrey Anne S. Bassett Christine Kupprion J?rg Drenckhahn Mark W. Norman Ludwig Thierfelder Susan N. Stuckless Elizabeth L. Dicks William J. McKenna Sean P. Connors | 2005 | Journal of the American College of Cardiology2005，，3： | 1 |
| 17 | Electrocautery a s a factor in Seroma formation following mastectomy显示文摘 | Susan O'Connor | 1998 | Am J Surg1998，176，1： | 1 |
| 18 | 护理行业如何应对数字化未来显示文摘护理行业必须投资并引领数字健康的发展,努力与各方合作研究输出患者和公众需要的数字化工具。数字技术对全球护理行业的影响不断增加:人工智能(AI)和机器人系统的影响力与日俱增;社会对手机、网络、社交媒体高度依赖,尤其是新型冠状病毒肺炎疫情暴发后,社会越来越依赖于远程医疗及其他通过虚拟手段进行的医疗服务。 | Richard G Booth Gillian Strudwick Susan McBride Siobhán O′Connor Ana Laura Solano López 李高华(译) | 2022 | 中国医院院长2022，18，23： | 1 |
| 19 | Electrocautery as a factor in seroma formation mastectomy显示文摘 | Kathaleen AP Susan O Connor | 1998 | Am J Surg1998，176，1： | 1 |
| 20 | Testing a new cognitive behavioural treatment for obesity: A randomized controlled trial with three-year follow-up显示文摘 | Zafra Cooper Helen A. Doll Deborah M. Hawker Susan Byrne Gillie Bonner Elizabeth Eeley Marianne E. O’Connor Christopher G. Fairburn | 2010 | Behaviour Research and Therapy2010，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员